CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Collaborator: Jining Medical University
• Treatments: Decitabine

Criteria

Inclusion Criteria:

• Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.

Exclusion Criteria:

• Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month